Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GRI Bio ( (GRI) ) has provided an announcement.
On January 8, 2026, GRI Bio reported additional positive immune profiling data from its Phase 2a clinical trial of GRI-0621 in idiopathic pulmonary fibrosis, showing inhibition of invariant NKT cells and a shift toward an anti-fibrotic immune profile, with increased interferon-gamma and reduced pro-fibrotic cytokines including IL-4, IL-13, IL-17A, IL-22 and TGF-β across multiple immune cell types in lung and blood samples. These mechanistic findings, which align with previously disclosed safety, tolerability and lung function benefits and suggest disease-modifying activity and fibrosis reversal, bolster clinical proof-of-concept for GRI-0621 and support its differentiation from existing IPF therapies; separately, the company noted that its December 2025 public offering has lifted stockholders’ equity above Nasdaq’s $2.5 million minimum, helping to stabilize its listing compliance position.
The most recent analyst rating on (GRI) stock is a Hold with a $0.24 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
Spark’s Take on GRI Stock
According to Spark, TipRanks’ AI Analyst, GRI is a Neutral.
The score is primarily held down by weak financial performance (large losses and continued cash burn) and bearish technicals (price far below key moving averages with negative MACD). Valuation is constrained by negative earnings, while recent clinical-trial and financing news provides some support but is offset by Nasdaq non-compliance risk.
To see Spark’s full report on GRI stock, click here.
More about GRI Bio
GRI Bio is a clinical-stage biopharmaceutical company developing immune cell modulators to treat inflammatory, fibrotic and autoimmune diseases, with a core focus on targeting Natural Killer T (NKT) cells to interrupt disease progression and restore immune homeostasis. Its lead oral candidate, GRI-0621, an RARβγ agonist that inhibits invariant NKT cell activity, is being developed for idiopathic pulmonary fibrosis, while a separate pipeline of diverse NKT agonists targets systemic lupus erythematosus, supported by a proprietary library of more than 500 compounds.
Average Trading Volume: 1,779,286
Technical Sentiment Signal: Sell
Current Market Cap: $3.06M
For a thorough assessment of GRI stock, go to TipRanks’ Stock Analysis page.